Equities analysts expect Esperion Therapeutics Inc (NASDAQ:ESPR) to report ($1.85) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Esperion Therapeutics’ earnings. The highest EPS estimate is ($1.66) and the lowest is ($2.04). Esperion Therapeutics reported earnings of ($1.71) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 8.2%. The firm is expected to issue its next earnings results on Thursday, August 1st.
On average, analysts expect that Esperion Therapeutics will report full-year earnings of ($2.10) per share for the current year, with EPS estimates ranging from ($3.01) to ($0.77). For the next fiscal year, analysts anticipate that the company will report earnings of ($3.59) per share, with EPS estimates ranging from ($6.99) to ($0.40). Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that follow Esperion Therapeutics.
Esperion Therapeutics (NASDAQ:ESPR) last announced its earnings results on Wednesday, May 8th. The biopharmaceutical company reported $3.07 EPS for the quarter, beating the Zacks’ consensus estimate of $0.64 by $2.43. The business had revenue of $145.42 million for the quarter, compared to the consensus estimate of $69.35 million. During the same quarter last year, the firm posted ($1.73) EPS.
In other news, Director Nicole Vitullo sold 15,329 shares of the business’s stock in a transaction that occurred on Tuesday, March 19th. The shares were sold at an average price of $44.73, for a total value of $685,666.17. Following the completion of the sale, the director now directly owns 8,319 shares in the company, valued at approximately $372,108.87. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Timothy M. Mayleben acquired 5,000 shares of the stock in a transaction dated Wednesday, March 20th. The stock was acquired at an average price of $43.48 per share, with a total value of $217,400.00. Following the completion of the acquisition, the chief executive officer now owns 56,163 shares in the company, valued at approximately $2,441,967.24. The disclosure for this purchase can be found here. Insiders own 7.70% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Rhumbline Advisers increased its position in Esperion Therapeutics by 45.2% during the fourth quarter. Rhumbline Advisers now owns 31,583 shares of the biopharmaceutical company’s stock worth $1,453,000 after buying an additional 9,836 shares in the last quarter. BB Biotech AG lifted its holdings in Esperion Therapeutics by 3.4% in the fourth quarter. BB Biotech AG now owns 3,392,964 shares of the biopharmaceutical company’s stock valued at $156,076,000 after acquiring an additional 110,000 shares during the period. Hsbc Holdings PLC acquired a new position in Esperion Therapeutics in the fourth quarter valued at approximately $11,067,000. Bailard Inc. lifted its holdings in Esperion Therapeutics by 561.1% in the first quarter. Bailard Inc. now owns 59,500 shares of the biopharmaceutical company’s stock valued at $2,389,000 after acquiring an additional 50,500 shares during the period. Finally, SG Americas Securities LLC acquired a new position in Esperion Therapeutics in the fourth quarter valued at approximately $203,000.
Shares of NASDAQ ESPR traded up $2.14 during mid-day trading on Monday, hitting $51.31. The company had a trading volume of 420,490 shares, compared to its average volume of 584,658. The firm’s 50-day moving average price is $48.74. Esperion Therapeutics has a 12 month low of $36.06 and a 12 month high of $60.99. The company has a market cap of $1.32 billion, a price-to-earnings ratio of -6.81 and a beta of 1.87.
About Esperion Therapeutics
Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.
Read More: How Do You Calculate Return on Equity (ROE)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.